June 26, 2019, Oxford, UK and Osaka Japan–Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, and Santen Pharmaceutical Co., Ltd. (Santen), the market leader for prescription ophthalmic pharmaceuticals in Japan with a global presence in over 60 countries, today announced that they have entered into an R&D… Read More
Oxford, UK – 29 May 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to Novo Holdings’ agreement to subscribe for 6,568,024 new ordinary shares in Oxford Biomedica (the “Subscription Shares”) at a price… Read More
Oxford, UK – 28 May 2019: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that Novo Holdings A/S (“Novo Holdings”), has agreed to invest up to £53.5 million in the Group in return for new ordinary shares representing up to… Read More
Oxford, UK – 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between… Read More
– Under terms of the agreement with Axovant signed in June 2018, this has triggered a $15 million milestone to Oxford Biomedica Oxford, UK – 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, notes that Axovant Gene Therapies Ltd. (NASDAQ: AXGT) has announced the… Read More
Oxford, UK – 26 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Kymriah® (tisagenlecleucel) for the treatment of two distinct indications – CD19-positive relapsed or refractory (r/r) B-cell… Read More
Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group today announces preliminary results for the year ended 31 December 2018. FINANCIAL HIGHLIGHTS • Gross income increased by 72%… Read More
Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group today announces preliminary results for the year ended 31 December 2018. FINANCIAL HIGHLIGHTS • Gross income increased by 72%… Read More
Oxford, UK – 12 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that it has entered into a research and development collaboration with Microsoft Research to improve the yield and quality of next generation gene therapy vectors using the cloud and machine learning. Read More
Oxford, UK – 11 March 2019: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes Axovant’s update on the Phase 2 SUNRISE-PD study of AXO-Lenti-PD. Axovant reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing… Read More
London, UK – 8 February 2019: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, will be announcing its Preliminary Results for the year ended 31 December 2018 on Thursday 14 March 2019. A briefing for analysts will be held at 12:00pm GMT… Read More
Oxford, UK – 7 February 2019: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, has been informed that as part of a company-wide portfolio review, Sanofi intends to seek a new partner for Oxford Biomedica’s outlicensed ophthalmology gene therapies, SAR422459 for Stargardt… Read More